logo
5th BEYOND Expo 2025 Creates an Enduring Legacy for Asian Tech Innovation

5th BEYOND Expo 2025 Creates an Enduring Legacy for Asian Tech Innovation

Yahoo8 hours ago

A record number of exhibitors and unprecedented investor participation defined this year's success. New business matchmaking milestones further elevated BEYOND Expo 2025.
Fund at First Pitch, Innovation Awards, Founder Stage and Founders Club Among Key Initiatives Supporting Entrepreneurs from across Asia.
MACAO, June 9, 2025 /PRNewswire/ -- The 5th BEYOND Expo concluded at The Venetian® Macao's Cotai with unprecedented momentum, cementing its role as a cornerstone for Asian tech innovation under the theme "Empowering Asia, Bridging the World." From inspiration by startups to wisdom shared by Alibaba Group's Chairman Joe Tsai, tech leaders and visionaries illustrated BEYOND Expo's commitment to supporting tech innovation in Asia. This year's BEYOND Expo attracted a record-breaking 25,000+ visitors, 800+ exhibitors, 300 media representatives, and over 800 investors, including more than 300 family offices and LPs, from over 120 countries — the highest numbers to date.
Covering sectors from AI, Healthcare, Mobility, Property Tech, Clean Energy, Robotics, Fashion Tech, Sports Tech, to Web3, this year marked the largest and most content-rich BEYOND Expo to date. Beyond the breadth of industry focus, BEYOND Expo also deepened its commitment to regional collaboration through a series of forums spotlighting strategic markets such as Southeast Asia, Japan, the Middle East, Latin America, and Europe. This dual emphasis on sector innovation and regional opportunity positioned BEYOND Expo as one of the most prominent and impactful pan-Asian tech gatherings ever held.
BEYOND Expo Co-Founder Dr. LU Gang said, "This year there has been a tremendous energy around BEYOND Expo, fueled by Asia's rapid rise in frontier technologies and a greater desire for inter-Asian collaboration and cooperation. The products and solutions on display demonstrate just how much AI is transforming so many aspects of our lives, from the food we eat and the clothes we wear to how we interact with each other. Our ecosystem partners, including media, investors, incubators, and suppliers, are driving this momentum and nurturing next-generation technologies."
BEYOND Expo recognized some of these innovators by presenting 25 Innovation Awards and hosting competitions such as Fund at First Pitch (FAFP), which attracted 150 competitors. JumpStart Media Executive Chairman James Kwan chaired the 2025 FAFP finale, which featured three high profile investors as judges: Artest Management Group (AMG) Chairman, Metta World Peace; Gobi Partners Co-founder and Chairperson, Thomas Tsao, and Lingotto Innovation Managing Partner & Co-Head, Morgan Samet.
BEYOND Expo Co-Founder Jason Ho added, "The impact of BEYOND Expo 2025 extends beyond the event itself. It has matured into a year-round ecosystem with the BEYOND Global Network and BEYOND Founders Club, initiatives that support the global expansion of Asian tech companies and foster knowledge and resource sharing among entrepreneurs, driving technological advancements to address global challenges."
Most International Speaker Lineup and Dynamic Stage Experience in BEYOND's History
During the three-day exhibition, BEYOND Expo delivered its most internationally diverse and intellectually stimulating content lineup ever. More than 300 speakers from across the globe, including Greater China, the United States, United Kingdom, Portugal, the Netherlands, Belgium, Brazil, Mexico, UAE, Singapore, Japan, South Korea, Thailand, Malaysia, Indonesia, Vietnam, Pakistan, and beyond, took the stage to share bold ideas and transformative insights.
Seven thematic stages were strategically placed across the expo floor, offering an immersive and accessible experience for all attendees. From visionary keynotes to dynamic roundtables, these sessions spanned global trends and regional collaboration, across topics such as:
Global Vision Summits: The BGlobal Summit, Global Investment Summit, Wealth Summit and Cross-Border E-commerce Ecosystem Forum explored how Asian innovators are scaling globally.
Regional Collaboration Forums: Asia-Europe Tech Forum, Asia-Latam Tech Forum, ORIGIN Southeast Asia Conference, Japan Tech Forum, and the Zayed Sustainability Prize China Forum created rare opportunities for cross-regional partnerships and investment dialogues.
Frontier Tech Spotlights: AI Summit, Web3 + AI Forum, Founders Talk, Transportation & Mobility Summit, Sports Tech Forum, Fashion Tech Forum, International Industrial Design Forum, and Gen Z Founder Forum brought cutting-edge conversations and industry innovation to the forefront.
Women in Tech: The SheTech Summit championed greater representation and leadership for women in the tech ecosystem.
This comprehensive summit program reinforced BEYOND Expo's status as a leading platform for driving innovation, collaboration, and growth in Asia's technology ecosystem.
A Special Focus on Asia's Unicorn Founders
The Opening Ceremony on May 21 convened some of the most influential minds in Asian tech to explore the theme "What's Next?". Among the featured speakers were Dr. Jian Wang, President of Zhejiang Lab and Founder of Alibaba Cloud; Carl Pei, Co-founder and CEO of Nothing; Dr. Burt Guo, CEO and Chief Scientist of Sichuan Aerofugia; Yuekai Zhao, Co-founder of Agile Robots SE; and Jingkang Liu, Founder of Insta360. A standout moment was the roundtable with unicorn founders, where these leaders exchanged bold ideas on scaling globally from Asia, a region rapidly emerging as the heartbeat of next-gen innovation.
Building on that momentum, the two-day Founder Talk featured over 30 trailblazing founders driving breakthroughs in AI, robotics, consumer tech, and sustainability. The stage also welcomed over 25 rising stars at the Gen Z Founder Forum and Gen Z Awards Ceremony, where young innovators showcased tech-driven solutions to global challenges. From unicorn visionaries to next-generation disruptors, BEYOND Expo celebrated the full spectrum of entrepreneurial ambition shaping the future of Asia and beyond.
Media Day Previewed BEYOND Expo 2025's Innovation
Held ahead of the main exhibition, the Media Day welcomed Beyond Expo product showcases, Media Day facilitated meaningful exchanges between innovators and the global press, setting the stage for a high-impact expo with worldwide reach.
A showcase for the tech-inspired products of the future
BEYOND Expo showcased over 1,000 high-tech products, targeting daily lifestyle and sustainability solutions. These included biodegradable materials, enhanced earphones and speakers, smart eyewear, healthy food, humanoids, medical devices, robotic pets, sleeping aids, and future mobility solutions. B2B applications included AI-reality-inspired software, medical devices, energy-saving and industrial robots.
Unmatched B2B Engagement and Industry Matchmaking
For the first time, BEYOND Expo hosted multiple on-site business matchmaking sessions over three days, connecting key industry players. Major corporations such as China State Construction International, China Taiping, Sands China, CATL, Tokyu Land Corporation, BMW Group, Sony, Makuake, Mitsubishi Estate, and Panasonic participated, signaling strong demand for real-time, high-value engagement between corporates and innovators. These sessions provided both sides with an efficient platform to identify strategic partners and explore collaborative opportunities.
International Delegations and Buyer Groups Expand Global Reach
This year also saw the participation of numerous international delegations and "buyer groups," further amplifying BEYOND Expo's reach. Representatives from Deloitte China, BMW Group, Japanese buyer groups, Western crowdfunding platform executives, and prominent overseas influencers all engaged with exhibitors, many of whom reported valuable feedback and new partnership leads. BEYOND Expo was positioned as a global gateway for companies aiming to scale across Asia and beyond, while spotlighting the region's confidence and capacity in innovation.
Backing the Region's Boldest Innovators
BEYOND Expo further strengthened its commitment to supporting emerging companies with expanded programming tailored for startups. At the heart of Growth Park, a newly launched multi-purpose stage served as a high-impact arena for product unveilings, startup-focused events, and strategic partnership announcements. The Demo Stage, a headline feature of this space, gave rising tech companies the chance to debut their latest innovations in front of a global audience, including investors, media, and industry leaders.
After Hours: Where Innovation Met Entertainment
As day turned to night, BEYOND Expo 2025 transformed into a vibrant celebration where technology and culture seamlessly converged. Each evening featured exclusive events that blended immersive entertainment with meaningful networking opportunities. From Welcome Night and Gala Dinner to dynamic pool parties energized by live DJs, an electrifying performance by Jax Jones, and the breathtaking Cirque Le Soir circus spectacle, BEYOND Expo offered unforgettable experiences that extended the spirit of innovation well beyond the conference halls.
BEYOND Expo 2025 Partners
BEYOND Expo 2025 was made possible with the generous support of Strategic Partners China State Construction International Holdings Limited and China Taiping; Platinum Partners Taobao 88VIP and Macau Pass | MPay; Gold Partner Nam Kwong (Group) Company Limited; Sustainability Partner the Zayed Sustainability Prize; and Venue Partner Sands China Ltd. Additional partners included Asian Family Legacy Foundation, ChainNeXT, Design School of Hunan University, Founders Breakfast, Greenwich Economic Forum, GWA, MAP, INNOBAKER, IESt, Lushan Laboratory, ReGACY Innovation Group, RMI, Sherewires, SIEF, TNGlobal, wteam, and yehyehyeh.
A full list of participating companies can be found here: BEYOND EXPO 2025
About BEYOND Expo
The BEYOND International Technology Innovation Expo (BEYOND Expo) is Asia's leading annual technology event. Serving as a dynamic platform since 2021, BEYOND Expo not only showcases global technological innovations but also provides a unique opportunity to foster innovation upgrades across diverse industries and regions.
BEYOND Expo has attracted participation from Asia's Fortune 500 companies, multinational corporations, unicorn companies, and emerging startups. Through a multifaceted approach involving expos, summits, and various activities, BEYOND Expo has successfully cultivated an innovative ecosystem, propelling collective development in the Asia-Pacific region and the global technology innovation industry. www.beyondexpo.com
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/5th-beyond-expo-2025-creates-an-enduring-legacy-for-asian-tech-innovation-302476028.html
SOURCE Beyond EXPO

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains
28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains

Yahoo

time2 hours ago

  • Yahoo

28bio Announces Nexon™ Neurotechnology Platform Powered by Engineered Human Brains

Exhibits complex neurological processes—including memory, learning, and cognition—and predicts human outcomes in preclinical drug development NEW ORLEANS, June 9, 2025 /PRNewswire/ -- 28bio today announced the Nexon™ neurotechnology platform—a major advancement in understanding human brain function. The platform integrates tissue engineering, neural interfacing and AI to engineer human brains at-scale and replicate complex neurological processes. The Nexon™ platform is now being used to improve the prediction of therapeutic efficacy and toxicity in humans, with several of the world's largest pharma companies already integrating Nexon™ into their drug development workflows. The Nexon™ platform also incorporates Organoid Intelligence (OI). The growing field of OI combines human brain organoids with brain-machine interfaces to model memory, learning, and cognition in vitro, offering novel functional cognitive biomarkers with the potential to reshape drug development in neurodegenerative disorders including Alzheimer's disease. Neurological drug development faces some of the highest failure rates in the pharmaceutical industry, due to poor translatability of animal models. Despite promising preclinical study results, many therapies ultimately fail in humans—contributing to a growing neurological health crisis and need for more predictive, human-relevant models. "We engineer human brains capable of elucidating the complexity of neurological processes and produce predictive data needed to change the trajectory of neurological drug development," said Alif Saleh, CEO of 28bio. "Industry and regulators are urgently asking for solutions to develop better neurological drugs faster and cheaper." About 28bio28bio is a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions. Its Nexon™ platform integrates tissue engineering, neural interfacing, and AI to reverse today's neurological health crisis by improving the ability to predict which therapies will work in humans. 28bio is committed to advancing ethical standards in the development of brain organoid technology and engineered human cognition. For more information, visit View original content to download multimedia: SOURCE 28bio Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

High Growth Tech Stocks To Watch In Europe June 2025
High Growth Tech Stocks To Watch In Europe June 2025

Yahoo

time2 hours ago

  • Yahoo

High Growth Tech Stocks To Watch In Europe June 2025

As the European markets experience a boost, with the STOXX Europe 600 Index climbing by 0.90% amid easing inflation and supportive monetary policy from the European Central Bank, investors are increasingly focusing on high-growth sectors such as technology. In this environment, identifying promising tech stocks involves looking for companies that can leverage favorable economic conditions and technological advancements to drive substantial growth. Name Revenue Growth Earnings Growth Growth Rating Intellego Technologies 30.80% 45.66% ★★★★★★ Archos 21.07% 36.58% ★★★★★★ KebNi 21.51% 66.96% ★★★★★★ Pharma Mar 29.61% 44.92% ★★★★★★ Bonesupport Holding 29.14% 56.14% ★★★★★★ argenx 21.50% 26.61% ★★★★★★ Skolon 31.51% 99.52% ★★★★★★ Xbrane Biopharma 24.95% 56.77% ★★★★★★ Diamyd Medical 86.29% 93.04% ★★★★★★ Elliptic Laboratories 36.33% 78.99% ★★★★★★ Click here to see the full list of 226 stocks from our European High Growth Tech and AI Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Growth Rating: ★★★★★★ Overview: argenx SE is a commercial-stage biopharma company focused on developing therapies for autoimmune diseases across several countries including the United States, Japan, China, and the Netherlands, with a market cap of €31.52 billion. Operations: argenx focuses on developing therapies for autoimmune diseases, generating revenue primarily from its biotechnology segment, which reported $2.64 billion. The company's operations span multiple countries, including the United States, Japan, China, and the Netherlands. argenx SE has demonstrated remarkable growth with a surge in revenue to $807.37 million, doubling from the previous year's $412.51 million, alongside transitioning from a net loss to a substantial net income of $169.47 million. This financial turnaround is underscored by robust R&D commitments, crucial for sustaining innovation and competitiveness in the biotech landscape. The firm's recent CHMP nod for VYVGART® in CIDP treatment further highlights its strategic focus on expanding therapeutic applications, promising continued relevance and impact within the healthcare sector. Click here to discover the nuances of argenx with our detailed analytical health report. Understand argenx's track record by examining our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Believe S.A. is a company that offers digital music services to independent labels and local artists across various regions including France, Germany, the rest of Europe, the Americas, Asia, Oceania, and the Pacific with a market cap of approximately €1.72 billion. Operations: The company's revenue primarily comes from Premium Solutions, generating €924.24 million, while Automated Solutions contribute €64.59 million. Believe, a European tech entity, is navigating its path towards profitability with expected earnings growth of 96.9% annually. Despite current unprofitability, its revenue growth outpaces the French market's average at 13.4% per year compared to 5%. This growth trajectory is supported by strategic moves such as the proposed acquisition by TCMI Inc., EQT X, and Denis Ladegaillerie for a €57.9 million stake, enhancing financial stability and market presence. Moreover, Believe's commitment to R&D aligns with industry demands for continuous innovation, ensuring it remains competitive in the dynamic tech landscape. Get an in-depth perspective on Believe's performance by reading our health report here. Examine Believe's past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★★☆ Overview: Comet Holding AG, along with its subsidiaries, delivers X-ray and radio frequency (RF) power technology solutions globally across Europe, North America, and Asia, with a market capitalization of CHF1.79 billion. Operations: The company generates revenue through three main segments: X-Ray Systems (CHF115.89 million), Industrial X-Ray Modules (CHF94.57 million), and Plasma Control Technologies (CHF247.39 million). Comet Holding AG, a Swiss tech firm, is making notable strides with an earnings growth of 37.3% annually, significantly outpacing the local market's average of 10.7%. This robust performance is further underscored by its revenue increase of 12.2% per year, which also surpasses the Swiss market growth rate of 4.2%. Notably, Comet's commitment to innovation is evident in its R&D spending, crucial for maintaining technological leadership in a competitive sector. Recent corporate actions include electing Benjamin Loh as Chairman and approving a dividend increase to CHF 1.50 per share, signaling strong governance and shareholder confidence amidst a promising financial trajectory marked by first-quarter sales surging by 37.5% year-over-year to CHF 111.2 million. Take a closer look at Comet Holding's potential here in our health report. Assess Comet Holding's past performance with our detailed historical performance reports. Dive into all 226 of the European High Growth Tech and AI Stocks we have identified here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTBR:ARGX ENXTPA:BLV and SWX:COTN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@

Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval
Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval

Business Upturn

time2 hours ago

  • Business Upturn

Glenmark Pharmaceuticals to launch Zanubrutinib (BRUKINSA) in India after DCGI approval

Glenmark Pharmaceuticals has announced the launch of zanubrutinib in India following approval by the Drugs Controller General of India (DCGI). The drug will be marketed under the brand name BRUKINSA®, developed by BeiGene (now BeOne Medicines), a global oncology company. This marks the introduction of the first Bruton's tyrosine kinase (BTK) inhibitor in India approved for the treatment of five B-cell malignancies: chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia (WM), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and follicular lymphoma (FL). BRUKINSA is approved in over 70 countries, backed by data from clinical studies such as ALPINE, ASPEN, and SEQUOIA. These trials have demonstrated consistent clinical outcomes across various B-cell cancers. The availability of BRUKINSA in India comes at a time when blood cancers continue to impact a large number of individuals. Estimates suggest that someone is diagnosed with blood cancer every five minutes in India, with annual deaths from the disease numbering around 70,000. The treatment has shown high response rates and the ability to maintain disease control in patients with different types of B-cell malignancies. It also offers dosing flexibility, allowing for once or twice-daily administration. In the ALPINE study, BRUKINSA was compared with ibrutinib in relapsed or refractory CLL and showed a lower rate of serious cardiac events and fewer treatment discontinuations due to cardiac-related issues. With its recent regulatory approval, BRUKINSA will now be available to patients in India who are affected by challenging hematological cancers. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store